There’s no such thing as a ‘generic vaccine’ - and that’s the problem
When you need a generic version of a blood pressure pill, you walk into a pharmacy and pick it up for a fraction of the brand-name price. It’s simple. Reliable. Common. But try that with a vaccine - any vaccine - and you hit a wall. There are no true generics. No cheap knockoffs. No easy switch. That’s not because no one wants to make them. It’s because it’s nearly impossible.
Vaccines aren’t pills. They’re living systems. Made from viruses, proteins, or mRNA instructions wrapped in tiny lipid bubbles. Each batch takes months to grow, purify, test, and package. One mistake in temperature, one impurity in the raw materials, and the whole batch is ruined. That’s why you can’t just copy a vaccine like you copy a tablet. The science doesn’t allow it. The regulations don’t allow it. And the infrastructure? It barely exists outside a handful of countries.
Who makes the world’s vaccines - and why it’s so concentrated
Just five companies - GSK, Merck, Sanofi, Pfizer, and Johnson & Johnson - control about 70% of the global vaccine market. That’s $38 billion in sales in 2020, locked up by a tiny group. These firms have spent decades building billion-dollar factories, perfecting supply chains, and winning regulatory approvals. No new player can walk in and compete without the same resources, time, and access to specialized materials.
India stands out as the exception. It’s the world’s largest vaccine producer by volume. The Serum Institute of India alone can make 1.5 billion doses a year. It supplies 70% of the vaccines used by the World Health Organization - including nearly all the measles and DPT shots given to children in poor countries. But even India’s massive output doesn’t mean it’s in control. Over 70% of the key raw materials for its vaccines - the cell cultures, buffers, and especially the lipid nanoparticles for mRNA shots - are imported from China and Europe. One export ban from the U.S. during India’s 2021 COVID wave cut global vaccine supply by half. That’s not resilience. That’s fragility.
The supply chain is a single thread holding up the world
Think of vaccine production like baking a cake that needs a rare spice only three companies in the world make. If one of them shuts down, the whole batch fails. For mRNA vaccines, the critical ingredient is lipid nanoparticles. Only five to seven suppliers globally can make them at the scale and purity needed. If one factory has a power outage, or a shipping delay, or a quality control issue, it ripples across continents.
And then there’s cold storage. The Pfizer-BioNTech COVID vaccine needs to be kept at -70°C. That’s not your home freezer. That’s industrial-grade ultra-cold chains, dry ice, specialized freezers, and constant monitoring. Most health clinics in rural Africa or Southeast Asia don’t have that. So even if doses arrive, they sit unused - and expire. In 2021, Médecins Sans Frontières found that in 23 African countries, less than 2% of the population had received a single dose of COVID vaccine. Meanwhile, doses were sitting in fridges, expiring in weeks, because there was no way to get them into arms.
Technology transfer isn’t just handing over a recipe
When the WHO set up a mRNA vaccine hub in South Africa in 2021, it seemed like a breakthrough. BioNTech, the German company behind Pfizer’s vaccine, agreed to share its technology. But 18 months later, the first doses rolled off the line - and even then, only at 100 million doses per year. That’s less than 1% of what the world needs. Why so slow? Because technology isn’t just data. It’s equipment. It’s trained workers. It’s supply chains you can’t buy off Amazon.
South Africa couldn’t get the right bioreactors. Couldn’t source the right filters. Couldn’t find enough technicians who knew how to handle mRNA without degrading it. The recipe was there. But the kitchen? The oven? The ingredients? Missing. And that’s the truth for every country trying to build vaccine capacity from scratch. It takes 5 to 7 years. $200 million to $500 million. And even then, you’re still dependent on imports for half your inputs.
Why low-income countries pay more - and get less
Here’s the cruel twist: the countries that need vaccines the most often pay the most - or wait the longest. Gavi, the global vaccine alliance, negotiates prices with manufacturers for low-income nations. But even then, the pneumococcal vaccine - which prevents pneumonia, a top killer of kids - still costs over $10 per dose in Africa. Meanwhile, wealthier countries bought the same vaccine for under $3 in bulk.
And when prices do drop, it’s not because of competition. It’s because one company, like the Serum Institute, decides to sell at cost to save lives. But even then, their margins are razor-thin. Building a single vaccine line costs more than $500 million. Selling doses for $3 or $4 means they’re barely breaking even. There’s no profit to reinvest. No incentive for private companies to scale up unless governments pay upfront. And most low-income countries can’t afford that.
Export bans, political choices, and the global blind spot
When India’s second wave hit in April 2021, the government stopped all vaccine exports. Not because it didn’t want to help. Because it couldn’t. Domestic demand had surged. Millions were getting sick. Hospitals were full. The Serum Institute had to choose: feed the world or feed its own people. It chose its own. And the world’s vaccine supply dropped by half overnight.
That’s not an accident. It’s a pattern. Countries with manufacturing capacity - whether India, the U.S., or Germany - will always prioritize their own populations first. That’s human. That’s political. But it’s also a systemic failure. The global system assumes that if you build enough factories, equity will follow. But without binding agreements, without shared responsibility, without investment in local capacity - it won’t.
Africa produces 60% of the world’s vaccine volume - but imports 99% of the vaccines it uses. That’s not a mistake. That’s a design flaw. African nations have the people, the science, and the will. But they don’t have the factories, the supply chains, or the political leverage to change it.
What’s actually changing - and what’s not
The U.S. FDA announced a pilot program in 2025 to fast-track generic drug approvals for manufacturers based in the U.S. It’s a step toward reducing dependence on China and India for pills. But it doesn’t touch vaccines. No such program exists for biologics. No regulatory shortcut can fix the complexity of cell culture or mRNA formulation.
The African Union wants to get to 60% self-sufficiency by 2040. That sounds ambitious. But it needs $4 billion in investment. Ten years. And global cooperation that doesn’t yet exist. Right now, most funding goes to buying doses, not building factories. That’s like giving someone a fish every day instead of teaching them to fish - and then wondering why they’re still hungry.
The hard truth: equity isn’t a technical problem. It’s a political one.
There’s no shortage of science. No lack of manufacturing know-how. India proved that. South Africa is proving it now. The Serum Institute showed that vaccines can be made cheaply. The problem is that the system doesn’t reward that. It rewards control. It rewards profit. It rewards countries that can afford to lock up supply.
If we want real change, we need to stop pretending vaccines are like pills. They’re not. They’re too complex, too fragile, too vital. And if we treat them like commodities - traded, hoarded, priced for profit - then we’ll keep seeing the same crisis over and over. The next pandemic won’t wait. The next child who dies from a preventable disease won’t care about patents or supply chains. They’ll just be gone.
What needs to happen next
- Invest in local manufacturing - not just in Africa, but in Southeast Asia and Latin America. Not as charity. As infrastructure.
- Share technology with binding agreements - no more voluntary sharing. If a company gets public funding, it must share its know-how.
- Build regional supply chains - stop relying on one country for lipid nanoparticles or cell substrates. Diversify. Stockpile.
- Link funding to production - donors must pay for factories, not just doses. A $100 million investment in a local plant saves thousands of lives over a decade.
- End export bans during crises - global health emergencies require global responsibility, not national panic.
There’s no magic fix. No quick win. But there’s a clear path: build capacity where it’s needed, pay for it upfront, and treat vaccines like the public good they are - not a product to be sold.
Written by Mallory Blackburn
View all posts by: Mallory Blackburn